Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. mexom

MEXOM SIGNED

Development and characterization of extracellular vesicles an innovative cell-free therapeutical product for treatment of stroke

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEXOM project word cloud

Explore the words cloud of the MEXOM project. It provides you a very rough idea of what is the project "MEXOM" about.

worldwide    mscs    training    intellectual    secreted    commercial    clinical    cargo    disability    evs    glp    cord    competences    anti    reinforce    models    independent    academia    skills    receive    mechanism    time    inflammatory    applicable    ex    industry    molecular    preconditioning    property    cell    deleterious    leader    gmp    preclinical    acute    vital    stem    societies    immunomodulatory    manufacturing    data    entrepreneurship    regenerative    mature    private    small    innovations    civil    demonstrated    highlight    first    policymakers    plays    brain    researcher    unmet    career    innovation    communication    host    medicine    indicate    vitro    medical    world    vivo    extracellular    enrichment    quality    clinically    regulations    msc    experiments    molecules    candidate    boosted    cells    stroke    effect    treatment    acquire    fellowship    transfer    public    inflammation    mesenchymal    action    stakeholders    exert    biology    he    failed    transferable    advancing    vesicles    micrornas    ischemic    grade    assurance    scientist    molecule    human   

Project "MEXOM" data sheet

The following table provides information about the project.

Coordinator		 THE CELL-FACTORY 

Organization address
address: GALILEILAAN 19
city: NIEL
postcode: 2845
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Belgium [BE]
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-09-03   to  2020-09-02

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CELL-FACTORY BE (NIEL) coordinator 160˙800.00

Map

 Project objective

Stroke is leading cause of long-term disability in Europe and worldwide with no effective treatment so far. Inflammation plays a vital role in brain’s response to ischemic stroke with deleterious consequences during early acute phase. Strong immunomodulatory effect of human mesenchymal stem cell (MSCs) demonstrated in many preclinical stroke models, however, has failed in clinical experiments. Recent preclinical data indicate that MSCs exert their anti-inflammatory effects via secreted extracellular vesicles (EVs) through microRNAs and this potential could be boosted by preconditioning MSCs ex vivo with small molecules. The aim of this Fellowship will be the determination of MSC-EVs anti-inflammatory mechanism of action specific for stroke for the first time.

The Host has developed clinical-grade technology (GLP/GMP) for human cord MSC-EVs manufacturing at large scale with anti-inflammatory action. During this Project the Researcher will receive training-through-research and will investigate the small molecule potential impact on MSC-EVs cargo enrichment with specific microRNAs. Then he will study candidate microRNAs anti-inflammatory potential in vitro on the key brain inflammation cells. The Researcher will acquire transferable knowledge in regulations, quality assurance, intellectual property and entrepreneurship. Novel competences will reinforce the Researcher as mature and independent scientist in the field of regenerative medicine with new career opportunities in private sector. Communication and dissemination will be carried out with all stakeholders, including academia, industry, civil societies, policymakers and general public.

The Researcher will transfer his molecular biology knowledge and skills, thus advancing the development of MSC-EVs product for treatment of stroke at the Host towards clinically applicable commercial innovation. This Fellowship will highlight Europe as world leader in innovations targeting unmet medical needs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEXOM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEXOM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

KiT-FIG (2019)

Kidney Transplantation - Functional ImmunoGenomics

Read More  

MarshFlux (2020)

The effect of future global climate and land-use change on greenhouse gas fluxes and microbial processes in salt marshes

Read More  

PaSION (2018)

A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy

Read More